Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.61 |
| ▸ | NPC1 | O15118 | 5/20 | 0.61 |
| ▸ | RAB9A | P51151 | 5/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.60 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.60 |
| ▸ | HPGD | P15428 | 1/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.60 |
| ▸ | TP53 | P04637 | 2/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.55 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.55 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.55 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.55 |
| ▸ | TGM2 | P21980 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 3/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3978246 | 0.95 | CYP17A1 (0.58) | SMN1; SMN2NPC1RAB9ACYP1A2CYP2D6 | |
| SCHEMBL7079625 | 0.91 | RAB9A (0.73) | SMN1; SMN2NPC1RAB9ACYP1A2CYP2D6 | |
| SCHEMBL13055402 | 0.89 | CYP17A1 (0.59) | SMN1; SMN2ALDH1A1GAAL3MBTL1CYP17A1 | |
| SCHEMBL30403272 | 0.88 | KMT2A (0.56) | SMN1; SMN2NPC1RAB9ACYP1A2CYP2D6 | |
| SCHEMBL29131710 | 0.87 | HPGD (0.59) | SMN1; SMN2NPC1RAB9AHPGDALDH1A1 | |
| SCHEMBL23619661 | 0.87 | SMN1; SMN2 (0.62) | SMN1; SMN2NPC1RAB9AHPGDALDH1A1 | |
| SCHEMBL12085977 | 0.86 | CYP17A1 (0.51) | SMN1; SMN2NPC1RAB9ACYP1A2CYP2D6 | |
| SCHEMBL4672586 | 0.85 | NPC1 (0.50) | SMN1; SMN2NPC1RAB9ACYP1A2CYP2D6 | |
| SCHEMBL20865536 | 0.83 | CYP17A1 (0.68) | SMN1; SMN2HTTL3MBTL1CYP17A1 | |
| SCHEMBL13783466 | 0.83 | NPC1 (0.51) | SMN1; SMN2NPC1RAB9ATP53ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 104 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108864127-A | A kind of oxygen bridge double-heptene sulfamide compound and the preparation method and application thereof containing different alkyl chain lengths | 武汉大学 | 2018-11-23 | — | — | CN | claimed |
| US-20230295368-A1 | CATALYST FOR DISSOCIATION OF BLOCKING AGENT FOR BLOCKED ISOCYANATES, AND THERMOSETTING COMPOSITION CONTAINING SAID CATALYST FOR DISSOCIATION OF BLOCKING AGENT | KOEI CHEMICAL COMPANY, LIMITED (JP) | 2023-09-21 | — | — | US | disclosed |
| US-20230295368-A1 | CATALYST FOR DISSOCIATION OF BLOCKING AGENT FOR BLOCKED ISOCYANATES, AND THERMOSETTING COMPOSITION CONTAINING SAID CATALYST FOR DISSOCIATION OF BLOCKING AGENT | KOEI CHEMICAL COMPANY, LIMITED (JP) | 2023-09-21 | — | — | US | disclosed |
| US-20230295368-A1 | CATALYST FOR DISSOCIATION OF BLOCKING AGENT FOR BLOCKED ISOCYANATES, AND THERMOSETTING COMPOSITION CONTAINING SAID CATALYST FOR DISSOCIATION OF BLOCKING AGENT | KOEI CHEMICAL COMPANY, LIMITED (JP) | 2023-09-21 | — | — | US | disclosed |
| US-11718704-B2 | Catalyst for dissociation of blocking agent for blocked isocyanates, and thermosetting composition containing said catalyst for dissociation of blocking agent | KOEI CHEMICAL COMPANY, LIMITED (JP) | 2023-08-08 | — | — | US | disclosed |
| US-11718704-B2 | Catalyst for dissociation of blocking agent for blocked isocyanates, and thermosetting composition containing said catalyst for dissociation of blocking agent | KOEI CHEMICAL COMPANY, LIMITED (JP) | 2023-08-08 | — | — | US | disclosed |
| US-11718704-B2 | Catalyst for dissociation of blocking agent for blocked isocyanates, and thermosetting composition containing said catalyst for dissociation of blocking agent | KOEI CHEMICAL COMPANY, LIMITED (JP) | 2023-08-08 | — | — | US | disclosed |
| CN-109563050-B | Amide salt compound, catalyst for polyurethane production and method for producing polyurethane resin | 广荣化学株式会社 | 2023-06-02 | — | — | CN | disclosed |
| CN-110475765-B | Preparation method of amide compound | 广荣化学株式会社 | 2023-04-07 | — | — | CN | disclosed |
| EP-3604287-B1 | PRODUCTION METHOD FOR AMIDATE COMPOUND | KOEI CHEMICAL CO (JP) | 2022-08-03 | — | — | EP | disclosed |
| EP-1531815-A1 | GLUCOKINASE ACTIVATORS | NOVO NORDISK A/S (DK) | 2005-05-25 | — | — | EP | disclosed |
| CN-1167681-C | Condensed indoline derivatives and their use as 5HT, in particular 5HT2C receptor ligands | О | 2004-09-22 | — | — | CN | disclosed |
| US-20040122235-A1 | Aryl carbonyl derivatives as therapeutic agents | VTV THERAPEUTICS LLC | 2004-06-24 | — | — | US | disclosed |
| WO-2004002481-A1 | ARYL CARBONYL DERIVATIVES AS THERAPEUTIC AGENTS | NOVO NORDISK A/S (DK) | 2004-01-08 | — | — | WO | disclosed |
| CN-1379761-A | Fused indoline derivatives and their use as 5HT, in particular 5HT2C, receptor ligands | VERNALIS RESAERCH LTD (GB) | 2002-11-13 | — | — | CN | disclosed |
| US-6100398-A | Transition metal-catalyzed process for preparing N-aryl amine compounds | YALE UNIVERSITY (US) | 2000-08-08 | — | — | US | disclosed |
| US-5849750-A | Dynemicin analogs | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 1998-12-15 | — | — | US | disclosed |
| US-5763451-A | Dynemicin analogs | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 1998-06-09 | — | — | US | disclosed |
| WO-1996003124-A9 | DYNEMICIN ANALOGS | — | 1996-03-14 | — | — | WO | disclosed |
| WO-1996003124-A1 | DYNEMICIN ANALOGS | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 1996-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295368-A1 | CATALYST FOR DISSOCIATION OF BLOCKING AGENT FOR BLOCKED ISOCYANATES, AND THERMOSETTING COMPOSITION CONTAINING SAID CATALYST FOR DISSOCIATION OF BLOCKING AGENT | IDH3A, RCOR1, MUS81 | SMN1; SMN2 2445/4885NPC1 4298/4885RAB9A 1971/4885 |
| US-11718704-B2 | Catalyst for dissociation of blocking agent for blocked isocyanates, and thermosetting composition containing said catalyst for dissociation of blocking agent | IDH3A, RCOR1, MUS81 | SMN1; SMN2 2445/4885NPC1 4298/4885RAB9A 1971/4885 |
| US-20040122235-A1 | Aryl carbonyl derivatives as therapeutic agents | GCK, GCKR, PDK2 | SMN1; SMN2 2958/4885NPC1 2201/4885RAB9A 3353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.